| Turchia | Austria | Spagna | |
| Immunoterapia | da $2,200 | da $30,000 | da $12,000 |
| Terapia con cellule CAR-T | da $150,000 | da $350,000 | da $330,000 |
| Terapia con Bacillo di Calmette-Guérin (BCG) | da $1,200 | da $2,400 | da $3,200 |
| Terapia biologica | da $5,500 | da $20,000 | da $15,000 |
| Immunoterapia per il tumore al polmone | da $18,000 | da $30,000 | da $30,000 |
Bookimed non aggiunge costi extra ai prezzi di Immunoterapia. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica per la tua Immunoterapia al tuo arrivo.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali in Immunoterapia e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di Immunoterapia.
Giorno 1
Giorno 2
Giorno 3
Giorno 4
Dal Giorno 5 al Giorno 7
Settimana 2
Settimana 3
Settimana 4
Si prega di notare che il caso di ogni paziente è unico e il programma sopra indicato può variare a seconda delle condizioni di salute del paziente e della risposta al trattamento.
Dr. Jaume Mora Graupera is a pediatric oncologist specializing in the treatment of neuroblastomas, gliomas, Ewing's sarcomas, and Wilms' tumors. He is the Director of the Hematology Oncology Department and Developmental Tumors Laboratory at Sant Joan De Déu - Barcelona Children’s Hospital. He received his medical degree from the University of Barcelona, went on to complete specialty training in pediatrics and fellowships in pediatric hematology oncology and molecular pathology of pediatric cancer at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in the USA. He has won multiple awards and is a member of various medical organizations.
Dr. Lucía González Cortijo is a medical oncologist with more than 20 years of experience. She has led the Medical Oncology Department at Hospital Universitario Quirónsalud Madrid since 2020. Her focus areas include breast and gynecologic cancers. She also works in precision oncology, targeted therapies, and immunotherapy.
She has been Principal Investigator in more than 20 Phase II–III clinical trials. She has also served as sub-investigator in over 50 international trials. She previously worked at Quirónsalud Madrid from 2009 to 2020. Before that, she was at MD Anderson Cancer Center Madrid from 2002 to 2009.
She holds an MD and a PhD (cum laude) from the Autonomous University of Madrid. She completed her Medical Oncology specialty training at Hospital 12 de Octubre. She also earned a Master’s in Molecular Oncology. She is a member of SEOM, ESMO, ASCO, and GEICAM. She is a university lecturer.
Dr. Ana Oaknin is a Medical Oncologist with expertise in angiogenesis, DNA repair, and immunology. She focuses on gynecological cancers. Dr. Oaknin earned her medical degree and MD in Medical Oncology from Complutense University of Madrid. She also holds a PhD from Universidad Autonoma de Barcelona.
Dr. Oaknin is Co-Chair of the GEICO Group. She is a faculty member for the Gyn-Track in the European Society of Medical Oncology. She represents Spain in the GOG and GCIG committees. Dr. Oaknin is an active member of ASCO, ESMO, and SEOM. She has published over 100 scientific articles and presentations. She also leads several clinical trials in ovarian, cervical, and endometrial cancer.
Dr. Jesus Soberino is an oncologist at Vall d’Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO). He specializes in breast cancer and melanoma. Dr. Soberino has led many phase 1–3 clinical trials. His work has helped approve important drugs, including CDK4/6 inhibitors for metastatic breast cancer and immunotherapies for melanoma.
His areas of expertise include endocrine therapy, managing hormone resistance, and developing new immunotherapies. Dr. Soberino is known for his patient-centered care. He actively collaborates in research to improve cancer treatment. He is accredited by VHIO and is a key member of the Breast Cancer and Melanoma Units.